Verkazia (Cyclosporine)
Brand Names: Verkazia
Methodology & AI Transparency ⓘ
Verkazia (Cyclosporine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Verkazia (Cyclosporine) represents a prescription brand-name calcineurin inhibitor immunosuppressant entry registered by Santen Incorporated with package codes 65086-001, 82667-014.
- 2 Real-world patient consensus: Branded calcineurin inhibitor immunosuppressant presentation of Cyclosporine (Santen Incorporated); generic reference: /meds/cyclosporine.
- 3 Typical cash cost range: 30-day cash pricing ranges from $141.67 discount cash to $375.43 walk-in retail (NADAC $1.8496/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Verkazia (Cyclosporine)): pruritus (4.5%), nausea (8.9%), headache (8.4%).
Ask our AI Specialists anything about Verkazia (Cyclosporine)
Verkazia (Cyclosporine) Mechanism, CYP450 Pathways & DailyMed Monograph
Verkazia (Cyclosporine) represents a prescription brand-name calcineurin inhibitor immunosuppressant entry registered by Santen Incorporated with package codes 65086-001, 82667-014. Reviewed against 2025-01-17 FDA SPL standards (1 mg/mL Emulsion; 25mg Bottle of Capsules), clinical deployment addresses Verkazia ophthalmic emulsion is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.
Verkazia achieves therapeutic action via Cyclosporine, engaging calcineurin inhibitor immunosuppressant physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 1 mg/mL Emulsion; 25mg Bottle of Capsules (registered by Santen Incorporated, NDC 65086-001, 82667-014), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Verkazia ($375.43 retail) with generic Cyclosporine ($141.67 low cash).
With Steady-state plasma equilibrium reached over 9–21 hour t½ intervals for Verkazia (Cyclosporine) residence kinetics and Approximately 48% to 60% enteral uptake across labeled Verkazia (Cyclosporine) strengths bioavailability, Verkazia (Cyclosporine) undergoes predominantly hepatic biotransformation with renal elimination of polar verkazia (cyclosporine) conjugates and establishes therapeutic activity over maximum serum exposure occurs 2–5 hours after verkazia (cyclosporine) dosing.
Standard adult regimens span 1 mg/mL Emulsion, 25mg Bottle of Capsules, 100mg Bottle of Capsules, 0.05% Box of 30 Vials (Emulsion), 0.05% Box of 60 Vials (Emulsion). Prescribers screen specifically against contraindicated in patients with prior serious allergic response to verkazia (cyclosporine) (ndc 65086-001); severe baseline organ impairment where cyclosporine accumulation exceeds safe therapeutic margins, while community micro-logs most frequently note nausea (8.9% of reports), headache (8.4% of reports), dizziness (6.8% of reports).
Reconcile eGFR-adjusted medications before escalating Verkazia (Cyclosporine) in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Verkazia (Cyclosporine) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Verkazia (Cyclosporine) (NDC 65086-001)
- Severe baseline organ impairment where Cyclosporine accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (16 Reports)
Verkazia (Cyclosporine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Verkazia (Cyclosporine))
Human clinical trial evidence for Verkazia (Cyclosporine) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Verkazia (Cyclosporine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.8496/unit (~$55.49/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $375.43 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $141.67 / mo | View logs ↓ |
Verkazia (Cyclosporine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Verkazia (Cyclosporine) RxNorm Concept ID | 2590613 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.8496 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $375.43 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $141.67 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Verkazia (Cyclosporine) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Verkazia (Cyclosporine): FDA labeling (2025-01-17, NDC 65086-001), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Verkazia (Cyclosporine) community threads and patient logs by age, biological sex, dosage, and treatment duration.